February 13th 2021, 4:00pm
For patients to maintain or improve their quality of life through their cancer treatment, it is pivotal that they communicate with their health care team.
February 12th 2021, 10:20pm
Clinical trials remain the gold standard when it comes to finding new treatment options for patients, particularly when it comes to renal cell carcinoma. But even if the results are positive and this combination proves to be beneficial, patients should still discuss all of their options with their oncologist to find the right sequence of treatment, says one expert.
February 12th 2021, 6:30pm
Front-line treatment with Opdivo plus Cabometyx improved health-related quality of life outcomes in patients with advanced renal cell carcinoma.
February 11th 2021, 9:56pm
Patients with metastatic non–clear cell renal cell carcinoma who receive immune checkpoint inhibitor–based regimens as a first treatment option may have improved survival, versus those who receive select targeted therapies.
February 11th 2021, 8:49pm
A higher starting dose of Lenvima, compared with a lower starting dose, prolonged the time that patients with renal cell carcinoma experienced negative effects on factors including social and physical functioning, financial difficulties and cogitative functioning over time.
February 11th 2021, 6:59pm
The combination of Lenvima plus everolimus was found to be an acceptable treatment option for patients who have previously received immunotherapy for clear cell renal cell carcinoma, according to the findings of an exploratory analysis of a phase 2 trial presented virtually at the 2021 ASCO Genitourinary Cancers Symposium.
January 22nd 2021, 7:48pm
After a fast-track designation, the Food and Drug Administration approved the combination of Cabometyx and Opdivo in the firstline setting for patients with advanced or metastatic renal cell carcinoma.
January 11th 2021, 2:00pm
Patients older than 75 years experienced more toxicity with mTOR inhibitors, tyrosine kinase inhibitors and checkpoint immunotherapy compared with those younger than 75 years, but researchers found that age did not impact outcomes like progression-free survival and overall survival.
January 5th 2021, 10:00pm
Patients with advanced or metastatic kidney cancer treated with the novel drug combination achieved a median progression-free survival of 9.2 months compared to 9.3 months among patients who received Cabometyx with a placebo.
January 5th 2021, 4:00pm
A roundup of some kidney cancer news and updates that occurred in 2020 that patients may have missed.
How TikTok Helped One Survivor Discover Connection and Community
Certain Dietary Patterns May Be Associated with Lower Risk of Colorectal Cancer
Managing the Stress of Medical Leave and Insurance Forms
‘I’m Not Always Happy, But I’m Happy Right Now’ with Endometrial Cancer
